ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Cardiome To Slash Workforce by 85% on End of Merck's Oral Development Program

By Chelsea Stevenson Cardiome Pharma Corp. (CRME) plans to reduce its workforce by about 85% in response to the termination of Merck & Co.'s (MRK) developing vernakalant oral program. All positions focused on internal research and certain supporting functions will be eliminated, Canadian-based Cardiome Pharma said. The reductions will result in up to $5 million in severance charges over the remainder of the year. In March, Cardiome's partner Merck discontinued its development of its oral vernakalant drug, which prevented atrial fibrillation. Cardiome had said it was disappointed with Merck's decision. Interim Chief Executive Dr. William Hunter said the board regrets the effects of the decision. Dr. Hunter replaced former Chief Executive Doug Janzen, who left the company last week. Cardiome Pharma reported a slightly narrower loss for its first quarter, citing clinical development efforts and pre-clinical research project expenditures. The latest quarter's loss also includes employee termination charges. The company said it will issue a further progress report in mid-August to its shareholders. Shares were off 2.3% to 43 cents in recent trading and have dropped 84% this year. Write to Chelsea Stevenson at chelsea.stevenson@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
04/26/201509:17:43MARKET SNAPSHOT: Apple, Energy, Health Care Earnings To Dominate...
04/26/201509:11:02If You Live in This State, You May Lose the Choice Whether to...
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?
04/24/201510:48:12Correction to Merck Hepatitis C Treatment Story Update
04/24/201510:26:22Merck: Hepatitis C Treatment Shows 95% Cure Rate -- Update
04/24/201510:02:02Illumina's Earnings Set Positive Tone for Biotech
04/24/201508:20:16Merck Says Experimental Hepatitis C Treatment Shows 95% Cure...
04/24/201507:57:21Merck Says Experimental Hepatitis C Treatment Shows 95% Cure...
04/24/201506:09:00Zulassungsrelevantes Phase-3-Studienprogramm C-EDGE von MSD zur...
04/24/201502:24:00Le programme d'essais pivot de phase III C-EDGE de MSD , qui...
04/24/201501:00:00Il programma registrativo di fase 3 C-EDGE di MSD per la valutazione...
04/24/201501:00:00Merckâs Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir S...
04/23/201514:59:00MSD gibt Ergebnisse einer Phase-2/3-Studie zu in der Erprobung...
04/23/201512:49:55Eli Lilly Results Top Expectations
04/23/201512:44:52Eli Lilly Results Top Expectations
04/23/201510:02:00MSD annuncia i risultati dello studio di fase 2/3 del trattamento...
04/23/201503:30:00Merck Announces Results from Phase 2/3 Study of Investigational...
04/23/201503:30:00MSD annonce les résultats de l'étude de phase 2/3 du traitement e...
04/22/201521:17:45Meet Pharma's Newest Movers and Shakers, Driving M&A
04/22/201520:12:06Meet Pharma's Newest Movers and Shakers, Driving M&A

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad